AR101891A1 - ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME - Google Patents
ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAMEInfo
- Publication number
- AR101891A1 AR101891A1 ARP150102964A ARP150102964A AR101891A1 AR 101891 A1 AR101891 A1 AR 101891A1 AR P150102964 A ARP150102964 A AR P150102964A AR P150102964 A ARP150102964 A AR P150102964A AR 101891 A1 AR101891 A1 AR 101891A1
- Authority
- AR
- Argentina
- Prior art keywords
- vasa
- sec
- amino acid
- acid sequence
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 101000830411 Homo sapiens Probable ATP-dependent RNA helicase DDX4 Proteins 0.000 abstract 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102100024770 Probable ATP-dependent RNA helicase DDX4 Human genes 0.000 abstract 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 2
- 102000055979 human DDX4 Human genes 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La divulgación además proporciona moléculas de ácido nucleico que codifican los mAb contra VASA, vectores de expresión, células huéspedes, métodos para la preparación de los mAb contra VASA, y métodos para la expresión de los mAb contra VASA. Finalmente, se divulgan métodos de uso de los mAb contra VASA para el aislamiento y/o la purificación de células que expresan VASA. Reivindicación 1: Un anticuerpo que se une específicamente a una proteína VASA humana que comprende una cadena pesada de inmunoglobulina y una cadena liviana de inmunoglobulina, donde la región variable de dicha cadena liviana comprende: (i) una región CDR1 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 83 - 88; (ii) una región CDR2 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 89 - 95; y/o (iii) una región CDR3 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 96 - 104. Reivindicación 2: Un anticuerpo que se une específicamente a una proteína VASA humana que comprende una cadena pesada de inmunoglobulina y una cadena liviana de inmunoglobulina, donde la región variable de dicha cadena pesada comprende: (i) una región CDR1 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 105 - 112; (ii) una región CDR2 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 113 - 121; y/o (iii) una región CDR3 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 122 - 131.The disclosure further provides nucleic acid molecules that encode mAbs against VASA, expression vectors, host cells, methods for the preparation of mAbs against VASA, and methods for the expression of mAbs against VASA. Finally, methods of using mAbs against VASA for the isolation and / or purification of cells expressing VASA are disclosed. Claim 1: An antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the variable region of said light chain comprises: (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 83-88; (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 89-95; and / or (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 96-104. Claim 2: An antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the variable region of said heavy chain comprises: (i) a CDR1 region that it comprises an amino acid sequence selected from the group consisting of SEC. ID. No. 105-112; (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 113-121; and / or (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 122-131.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051130P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101891A1 true AR101891A1 (en) | 2017-01-18 |
Family
ID=58698591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102964A AR101891A1 (en) | 2014-09-16 | 2015-09-16 | ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR101891A1 (en) |
| MA (1) | MA40086A1 (en) |
-
2015
- 2015-09-16 AR ARP150102964A patent/AR101891A1/en unknown
- 2015-09-16 MA MA40086A patent/MA40086A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA40086A1 (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| CO2018013500A2 (en) | Anti-pd-l1 antibodies and uses thereof | |
| AR102698A1 (en) | ANTIBODIES AGAINST CD73 AND ITS USES | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| PE20240111A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
| PE20190120A1 (en) | BINDING MOLECULES TO BCMA AND METHODS OF USE OF THEM | |
| PE20180480A1 (en) | FACTOR XI ANTIBODIES AND METHODS OF USE | |
| CL2019000119A1 (en) | Bispecific antibody binding proteins that specifically bind cd3 and cd123. | |
| PE20181044A1 (en) | ANTI-PD-1 ANTIBODIES AND COMPOSITIONS | |
| PE20211291A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| PE20190356A1 (en) | CHEMERICAL RECEPTORS AND METHODS OF USE OF THE SAME | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| AR101829A1 (en) | CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| AR095980A1 (en) | SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE | |
| ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
| AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES | |
| PE20151289A1 (en) | ANTIBODIES THAT JOIN THE TL1A AND ITS USES | |
| MX366359B (en) | Humanized antibodies against ceacam1. | |
| PE20180481A1 (en) | UNION TO TAU ANTIBODIES | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| ECSP18084153A (en) | Humanized anti-BASIGIN antibodies and their use | |
| CL2017000912A1 (en) | Antibodies that bind to ccr6 and its uses | |
| EA201790236A1 (en) | ANTIBODIES AGAINST VASA AND METHODS FOR THEIR PRODUCTION AND USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |